OrganaBio logo rev color
Contact
menu shape ham

By Sarah Alter, PhD, Lab Director at OrganaBio · Updated June 2026

RUO vs. cGMP Cell Therapy Starting Material: What the Transition Actually Requires

Most CGT programs source RUO starting material during research, then discover their supplier can’t offer cGMP-compliant material when it matters. The transition from RUO to cGMP is not primarily a compliance problem. It’s a sourcing architecture problem.

If the supplier you use for research can’t follow you into clinical manufacturing, you’ll pay for that decision at the worst possible time: when your team is already under pressure to file.

Section 1: What RUO and cGMP Actually Mean for Starting Material

RUO (Research Use Only)

RUO designation means the material is intended for preclinical research only. Not for human diagnostic use, not for therapeutic use, not for in vitro diagnostic use. RUO does not require cGMP manufacturing conditions or the documentation depth of a clinical lot release package. Supplier quality standards vary significantly at the RUO level — a supplier who applies thorough characterization methodology (infectious disease screening, immunophenotyping, HLA typing) to RUO material is giving you data that will matter later.

cGMP Starting Material

cGMP starting material is not an approved therapeutic product and is not for direct human use. When OrganaBio supplies a cGMP leukopak or cGMP CD34+ HSCs, those products are intended for further manufacturing — cell expansion, genetic modification, or formulation into a cell therapy drug product. The reason starting material matters for cGMP compliance is that FDA and international regulatory agencies assess the full manufacturing chain during IND review.

Documentation element RUO CoA (typical) cGMP lot release package
Cell counts and viability Yes Yes
Donor demographics Yes Yes
Infectious disease screening Varies by supplier Per 21 CFR 1271, required
Immunophenotype Varies by supplier Included
Full batch record with QA release No Required
Sterility testing No Required
Chain of custody / identity Minimal Full
Summary of Records (HCT/P) No Required
Medical Director review No Required

Section 2: The Transition Problem — Why Switching Suppliers Mid-Program Is Costly

A change in starting material supplier is a material change. It means different donors (different HLA profiles, different immunophenotyping, different collection histories), different processing SOPs (which affect cell activation state, viability, purity, and yield), and different equipment environments. The regulatory team must run a comparability exercise to demonstrate the new material is sufficiently similar to what was used in preclinical studies. If the earlier RUO material had minimal characterization, there may not be enough historical data to run a clean comparability.

The Phase I discovery — the most common failure mode: a program spends two or three years doing excellent preclinical work on RUO material from a supplier who only offers RUO, then realizes at the IND-enabling phase there is no cGMP path.

The comparability gap: a program sources cGMP material from a different supplier than their RUO material, assuming lot characteristics will be similar. They’re not. The regulatory team spends three months running comparability studies they didn’t budget for.

Section 3: Phase-Appropriate Sourcing — What Continuity Means

Use the same donor pool, the same processing SOPs, and the same characterization methodology across research and clinical phases. What changes as you advance is the documentation layer, not the underlying material.

Phase Grade typically expected What should stay consistent Risk if you switch suppliers here
Early RUO research RUO acceptable Characterization depth (HLA, immunophenotype, ID screen) Moderate — expensive to discover later
IND-enabling (late preclinical) cGMP increasingly expected Donor pool, processing SOPs, characterization methodology High — comparability exercise required
Phase I cGMP required Donor identity, full lot release documentation Catastrophic — program halted to find new source
Phase II/III cGMP, validated processes Traceability back to early studies Expensive regulatory exercise; timeline impact

The solution is not complicated. It’s a sourcing decision made early, with continuity as the selection criterion. The supplier you use for your first RUO experiments should be the supplier whose cGMP material goes into your Phase I manufacturing.

Section 4: What to Verify When a Supplier Claims to Offer Both

Are your RUO and cGMP products sourced from the same donor pool? If no, you’re dealing with two separate donor populations, and the comparability challenge exists from the start.

Do the same SOPs govern collection and processing across both grades? The difference between RUO and cGMP should be the documentation layer, not the manufacturing process. Ask for specifics: same anticoagulant, same time-to-processing targets, same density gradient methodology.

Can I access the same specific donor for repeat collections across both grades? Recallability is critical for bridging studies. Access to the same donor removes a variable from the comparability exercise.

Is donor characterization identical across grades? Ask specifically about HLA typing resolution, the infectious disease screening panel, and whether immunophenotyping scope is the same.

What does the cGMP lot release package actually include? Ask for a sample CoA and a redacted batch record. Look for QA release signature, sterility testing, deviation log, and Summary of Records.

What’s your process if we want to move into clinical manufacturing with you? A supplier with an integrated model will have a defined pathway: a clinical MSA, a tech transfer process, and a defined timeline.

Section 5: OrganaBio’s Approach

OrganaBio’s structure was built around the continuity problem. The same recallable donor pool at HemaCenter feeds both the RUO research product catalog and the cGMP manufacturing service. The SOPs governing collection, processing, and cryopreservation are the same across grades. What changes between RUO and cGMP lots is the documentation layer: batch records, QA release, sterility testing, chain of identity, and the clinical MSA.

Every donor in the pool receives 6-gene NGS HLA typing and infectious disease screening per 21 CFR 1271, regardless of whether their material is going into an RUO SKU or a cGMP manufacturing run. Researchers who use OrganaBio’s RUO products and then move to cGMP manufacturing work with the same donor pool, the same HLA and immunophenotype data, and the same processing history — without a sourcing transition.

For programs with specific donor requirements, OrganaBio offers a pre-screening service: define your criteria (HLA type, CMV status, immunophenotype markers, cell count requirements) and OrganaBio screens the donor pool against those criteria before committing to a full apheresis collection.

Discuss your IND-enabling strategy
View cGMP manufacturing services
Written by Sarah Alter, PhD, Lab Director at OrganaBio. Dr. Alter holds a PhD in Immunology from the University of Miami and an MSc in Microbiology from Florida Atlantic University. She is a Registered Patent Agent with 20+ years of immunology and cell biology research experience.
Request Free Sample
Linkedin-in Facebook-f Twitter Instagram

Andrew Larson

Managing Director, CPC Services

Andrew joins OrganaBio as a project manager with varied experience in project management, client relations, and process improvement.

Prior to OrganaBio, Andrew was a client relations manager for the cGMP nucleic acids business unit at Aldevron, coordinating and managing contracts at each stage of the contract lifecycle in support of cell and gene therapy program development. Andrew supported small- and large-scale biotechnology and pharmaceutical clients anywhere from pre-IND work through commercial supply chain establishment. Before Aldevron, Andrew was a project manager for the commercialization and business development department for Sanford Health, a worldwide hospital institution. At Sanford Health, Andrew helped manage medical device patent and prototype development efforts for employee innovations primarily in the cardiovascular, neurovascular, and software spaces. Andrew was also an engineer for Atirix Medical Systems and supported the buildout of automated analysis worksheets to streamline radiology department quality control procedures.

Andrew received his Bachelor of Science in Physics from Minnesota State University Moorhead and his Master of Science in Biomedical Engineering from the University of Minnesota. At the University of Minnesota, Andrew was part of the Center for Magnetic Resonance Research, assisting efforts to automate MRI dataset registration and workflow improvement.

Michael Dee

Associate Director, QC and Analytical Development

Michael Dee has spent the last 17 years researching the immune system. Initially studying the recombinant cytokine IL-2 and its role in T cell subset differentiation and function at the University of Miami. He also helped elucidate the lower level of TCR diversity of T regs required to prevent autoimmunity in mice. Michael also supported construction, cloning, production, purification, and testing both in vitro and in vivo a novel IL-2/IL2Rα complex currently under clinical development with BMS. Michael also was a member of the department of immunology’s program project delineating the effect of a novel Eg7GP96 heat shock protein vaccine on tumor immunity.

While at Immunity Bio (formerly Altor Biosciences), he helped to characterize over 20 novel drugs for immune modulation and treatment of cancer.  After Immunity Bio, Michael was a founding team member of HCW Biologics, where he continued his role in design and initial production and characterization of several novel biologics. He has experience with proof of principle experiments with the generation CAR-NK and CAR T cells. His research at HCW was highlighted by his discovery of a process using novel biologics to activate and expand CIML NK cells. The process and rights were sold to Wugen and is currently in Phase I clinical trials. He also is listed as an Inventor on patent number: US20210268022A1 on method of activating regulatory T cells.

Meram Alamoudi

Senior Cell Processing Specialist

Meram received her master’s degree in biomedical sciences from Barry University and bachelor’s in Biology from Palm Beach Atlantic University.

Before her position at OrganaBio, Meram conducted research at Larkin University where she worked on assessing the impact of Hurricane Maria on respiratory diseases in Puerto Rico, which provided her with insight into research investigation and analysis along with generation of grant documentation.

Valeria Beckhoff-Ferrero

Senior Bioprocess Scientist

Valeria Beckhoff Ferrero has over 8 years of experience in the fields of stem cell research and tissue engineering. Valeria received her Bachelor of Science in Biomedical Engineering, specializing in Biomaterials and Tissue Engineering, from Drexel University in Philadelphia. Valeria has expertise in problem solving and finding manufacturing solutions for isolating various types stem cells and other cell derived products from different tissues.

Before joining OrganaBio, Valeria was a lead manufacturing engineer at the Amnion Foundation. She aided in instituting a GMP infrastructure, including documentation, to manufacture clinical grade placental derived stem cells. In her role, she worked in perfecting isolation, culture, selection and cell maintenance processes for perinatal derived stem cells.

Valeria’s experience includes working as an Automation Engineer at the New York Stem Cell Foundation, where she aided in the creation and coding procedures for liquid handlers to manufacture induced pluripotent stem cells. At NYSF, Valeria researched new methods of sorting, reprogramming and differentiating iPSCs.

During her studies, Valeria worked at Thomas Jefferson University Hospital’s Radiation Oncology department, where she engineered various devices to aid in hyperthermia treatments. Additionally, Valeria co-authored multiple publications on magnetic resonance guided focused ultrasound and radiation antennas for hyperthermia treatments.

Marisa Reinoso

Director, Regional Scientific Sales

Marisa has experience leading marketing and sales life sciences programs for over a decade. Originally a lab researcher, she made the jump to marketing & sales in life sciences and never looked back.

At OrganaBio, she connects cell therapy developers on the West coast and in Asia with the healthy donor starting materials they need to develop their therapies. Prior to OrganaBio, she was the cell therapy marketing lead at Invetech, heading the launch of the company’s first cell therapy product. Marisa has led marketing programs at clinical supply companies Sherpa Clinical Packaging and PCI Pharma Services. In her spare time, Marisa enjoys traveling, eating, and pretending she’s a tennis player. She has a Bachelor of Arts in Biology from Reed College and an MBA from Portland State University.

Thelma Cela

Senior Director, Tissue Procurement

Thelma Cela is a top performing professional with over 25 years’ experience in management, leadership, business development and marketing fields with business acumen and skills in driving revenue and profit growth in multiple corporate cultures. Prior to joining OrganaBio, Thelma served as Senior Director for Health and Human Services for the Seminole Tribe of Florida. Her role had oversight for health clinics, health plan administration, the behavioral health department, and elder services. In this governmental administrative capacity, Thelma had primarily responsibility for the HHS’ divisions’ budget, capital projects, utilization management, efficiency, and efficacy.

Thelma’s prior work experiences include Vice President of Clinical Operations for OrthoNOW. In this role, she provided guidance on all clinical matters, set direction on clinical policies and procedures and monitoring healthcare policy changes. As the national Vice President of Clinical Operations, Thelma also designed, developed, and implemented guidelines and protocols and ensured compliance regarding overall patient experience.

Before joining OrthoNOW, Thelma had been recruited by Leon Medical Centers, a private healthcare company operating comprehensive medical centers to launch a new business line addressing the health and wellness of an aging population. As Director, Thelma researched, created, and launched the company’s Health Living Centers which provided first of its kind facilities in the South Florida market to offer services to the community of health aging.

Thelma has a proven track record in multiple corporate healthcare cultures having worked for Mercy Hospital where she was Senior Program Director of their Diabetes Treatment Center and Director of their Surgical Weight Loss Program. She enhanced these service lines awareness in the community, improved both lines’ clinical outcomes, and built volume growth while maintaining ongoing physician support. She served in a similar capacity for American Healthways.

Thelma earned her MBA from Miami Regional University where she graduated Cum Laude and her undergraduate degree in Psychology is from the University of Miami.

She serves on the advisory panel for Florida International University’s Women in Business Leadership Program helping future women become future business leaders through thought leadership, barrier destruction, and the power of influence.

Dominic Mancini

Vice President, Operations

Dominic Mancini brings 12 years of experience working the interfaces between Analytical Development, Process Development, Quality, and Manufacturing Science to OrganaBio. A lifelong learner, Dominic enjoys solving the many scientific and operational challenges presented in the field of cell and gene therapy.

Prior to OrganaBio, Dominic spent 8 years at Bluebird Bio as the company grew from 45 to 1200+ employees and from 1 clinical asset to a robust commercial pipeline. At Bluebird, Dominic initially supported the development and technology transfer of lentiviral vector manufacturing processes. As demand grew for lentiviral process and product characterization, Dominic led the development, qualification, transfer, and validation two commercial release methods. Dominic transitioned back to the Process Development organization to lead the vector manufacturing core team, increasing operational efficiency through a 5S implementation, process schedule intensification, and reverse technology transfer initiative. More recently, Dominic supported the build-out of bluebird’s Manufacturing Science & Technology team followed by the Data Systems & Analytics team, handling late-stage commercial asset support.

Dominic received his Bachelor of Chemical Engineering with Distinction from the University of Delaware. Dominic’s undergraduate research culminated in his thesis on heterologous expression of G-protein coupled receptors in Saccharomyces cerevisiae. After graduation, Dominic was the premier hire of the Zhou Laboratory at Brigham and Women’s hospital in Boston, MA. In three years, Dominic established an animal model of COPD and co-authored several papers with his collaborators in the Pulmonary division.

Christopher B. Goodman

Vice President, Quality & Regulatory Affairs

Christopher B. Goodman is a biopharmaceutical consultant and executive making a global impact in the cellular therapy technology arena. The scope of Christopher’s expertise encompasses Cellular Therapeutic Operations, Quality and Regulatory Affairs, Global Corporate Operations, Scientific Strategic Planning, Scientific R&D Collaborations, and Marketing & Commercialization.

Christopher recently joined OrganaBio as their Vice President of Regulatory Affairs. In this role, Christopher will be helping the company, its clients and partners navigate the complexities of the domestic and international regulatory requirements governing advanced cellular therapy products and manufacturing.

Previously, Christopher held positions with the Association for the Advancement of Blood and Biotherapies (AABB), Virgin Health Bank, Ventana Medical Systems, and Celgene.

While with AABB, he held the positions of Senior Director of New Products and Lead Quality Assessor, auditing both domestic and international organizations to known standards in an effort to promote and ensure patient quality care and manufactured product consistency and standardization within Cellular Therapy, Blood Banking, Transfusion Services, Perioperative and Donor Center industries and operations. He contributed greatly to the work of AABB’s accreditation program providing his deep breadth of knowledge and technical acumen on many committees during his tenure. His pioneering work in the realm of virtual assessments during the COVID pandemic allowed AABB to flex into the planning and execution of this novel approach to the maintenance of accreditation activities during a global travel crisis. His agile thinking and approach to planning provided as minimal disruption as possible to AABB’s customer facilities.

While working with Virgin Health Bank in the State of Qatar and the United Kingdom, Christopher advanced through a series of executive roles. He joined Virgin Health Bank as the Director of Operations, during which time he managed the successful design, and build out of a new state-of-the-art cGMP facility, the first in the Middle East. As Director and Chief Executive Officer, he directed the launch of the first Arab-centric stem cell bank, and strategically guided the organization to enhanced shareholder value and expansion across the Middle East and UK. In these roles, he also oversaw global corporate operations, research collaborations, product portfolio expansion, and regulatory framework.

Christopher managed the Detection and Chemistry Assay Development Group for Ventana Medical Systems, a global leader and innovator of tissue-based diagnostic solutions. In this role, he directed overall program goals, optimized resources, and guided technical and product direction in global regulated environments.

Prior to Ventana Medical Systems, he held the position of Director of Operations for the high-growth Cellular Therapeutics Division of Celgene. As a senior-level scientist and member of the executive team, he directed divisional operations, medical affairs and executed business and scientific strategic planning.

Danielle Smyla

Senior Director, Quality Assurance

Danielle Smyla, M.S., brings 14 years of Quality Assurance and GMP experience in the Biotechnology and Medical Device industries. Ms. Smyla is an established Quality Leader with expertise in the implementation, management and continuous improvement of Quality Management Systems for GMP operations.

Prior to joining OrganaBio, Danielle was a key member of the Quality Management team at Canon BioMedical, where she led the cross-functional development and implementation of their Quality Management System. She also managed a team of Quality Specialists and Sr. Specialists, coaching them in the implementation, management and identification of improvements to quality processes.

Ms. Smyla’s Quality-focused career is complimented by valuable hands-on experience in GMP product manufacturing, as well as R&D laboratory experimentation and formulation work in support of product development.

Danielle has earned a Master’s in Biotechnology from the Johns Hopkins University and a Bachelor of Science in Chemistry from the George Washington University.

Sarah Alter, Ph.D.

Lab Director

Sarah Alter, Ph.D., is Laboratory Director at OrganaBio, LLC, where she provides technical leadership across laboratory operations, process development, product manufacturing, and clinical sample processing services supporting cell and gene therapy developers worldwide. She brings more than 20 years of immunology and translational research experience spanning autoimmunity, oncology, and infectious disease.

Since joining OrganaBio in 2018, Dr. Alter has progressed through roles of increasing responsibility, first as Director of Immunology, leading development and manufacturing of human-derived immune cell products for immuno-oncology partners and clients; then as Senior Director of Scientific Affairs, where she served as immunology subject matter expert and shaped scientific strategy across new product launches, market analyses, and client engagements. She also served as founding Managing Director of HemaCenter, LLC, OrganaBio’s FDA-registered leukapheresis collection subsidiary, where she stood up operations, recruited the medical team, and authored governing protocols and SOPs.

Earlier in her career, Dr. Alter led preclinical R&D for IL-15–based immunotherapies at Altor BioScience (now ImmunityBio), contributing to programs that advanced into the clinic and co-authoring numerous peer-reviewed publications. She holds a Ph.D. in Immunology from the University of Miami Miller School of Medicine and an M.Sc. in Microbiology from Florida Atlantic University, and is a registered Patent Agent licensed to practice before the U.S. Patent and Trademark Office.

Carlos Carballosa, Ph.D

Vice President, Sales

Dr. Carlos Carballosa holds a doctorate in Biomedical Engineering from the University of Miami and currently leads global sales for OrganaBio as the VP of Sales. Since joining the company in 2018, Carlos has had a hand in managing all of OrganaBio’s products and services including perinatal tissue, apheresis material, and cell processing and cryopreservation support services for clinical trials.

Oscar Robles

Director, Quality Systems

Oscar Robles has over thirty years of experience in pharmaceutical and medical device industries. His main areas of expertise are in Quality Systems, Quality Assurance, Manufacturing Systems Validation, Computerized Systems Validation, implementation of GxP Computerized Systems and ERP Systems such as TrackWise, Electronic Document Management, JDEwards, SAP, and Oracle. Prior to joining OrganaBio, Oscar was a member of the Quality Management team at Apotex – Aveva Drug Delivery Systems for ten years. Oscar has earned a Master’s in Business Administration from Nova Southeastern University and a Bachelor of Science in Electrical Engineering from Florida International University.

Request Free Sample Free Sample